Most initial IO clinical trials excluded patients with early-stage hormone receptor–positive and human epidermal growth factor receptor 2–negative (HR+HER2–) breast cancers, considered unlikely to respond because of low levels of immune infiltrate. Here, NR4A1 is linked to breast carcinoma.